The present invention relates to dexamethasone for use in a method of reducing stem cell accumulation in the spleen in a human individual, the method comprising administering dexamethasone to the individual prior to stem cell treatment, and wherein the total dose of dexamethasone administered is equivalent to or greater than a dose of 2-3 mg in an adult male 129S1/SvmJ mouse.